Projects
Combination of targeted therapy and chemotherapy in acute lymphoblastic leukemia Ghent University
Acute lymphoblastic leukemia (ALL) is an aggressive leukemia that is most common in children and adolescents. Longterm ALL survival rates have significantly improved by the use of intensified chemotherapy and reach 80% in pediatric cases, and 60% in adult ALL, but are associated with substantial acute and long-term side effects. Moreover, the outcome of ALL patients with primary resistant or relapsed disease remains extremely poor en ...
Modelling of tumor control probability in preclinical targeted radionuclide therapy KU Leuven
Neuroendocrine tumors (NETs) are a heterogeneous group of neoplasms that originate from cells of the neuroendocrine system. Targeted radionuclide therapy (TRT) has become the standard treatment in the management of patients with inoperable or metastasized well-differentiated NETs (up to 90% of symptomatic patients). Peptide receptor radionuclide therapy (PRRT) employs an exclusive feature of well-differentiated NETs that is the overexpression ...
Autoantibodies in autoimmune-mediated thrombotic thrombocytopenic purpura: from mechanistic insights towards the first steps in targeted therapy KU Leuven
Predictive genetic markers for targeted therapy in gynaecological malignancies: bridging the gap between “one-size-fits-all” and more personalised treatment approach. KU Leuven
Even with today’s ongoing progress in diagnosis and treatment options, HGSOC is still characterized by poor long-term survival and high recurrence rates. Platinum-based chemotherapy and surgery are key in the treatment but development of resistance remains a major clinical problem. Recently, more targeted therapies, such as PARPi have been developed which could help to turn around the ‘one-chemo-fits-all’ approach. This breakthrough can have ...
lncRNAs as modifiers of melanoma progression and sensitivity to targeted therapy KU Leuven
Metastatic melanoma is the most aggressive and deadliest form of skin cancer. The difficulty in eradicating melanoma lies in its high degree of heterogeneity and plasticity. Melanoma intratumor heterogeneity arises, at least partly, through epigenetic (rather than genetic) reprogramming of proliferating cells into a phenotypically distinct invasive cell subpopulation. Understanding the molecular processes underlying melanoma heterogeneity is ...
Combination of targeted therapy and chemotherapy in acute lymphoblastic leukemia KU Leuven
Acute lymphoblastic leukemia (ALL) is an aggressive leukemia that is most common in children and adolescents. Long-term ALL survival rates have significantly improved by the use of intensified chemotherapy and reach 80% in pediatric cases, and 60% in adult ALL, but are associated with substantial acute and long-term side effects. Research from the past 10 years has identified several new targets for therapy in ALL, which can be targeted by ...
Combining targeted radionuclide therapy and cancer immunotherapy to advance precision medicine through innovation. Vrije Universiteit Brussel
A novel targeted therapy to treat bleeding in patients with a left ventricular assist device. KU Leuven
Understanding triple negative breast cancer dependence on serine biosynthesis: new insights for targeted therapy. KU Leuven
Breast cancer is the second leading causes of cancer death among women. This issue is of particular relevance for Belgium, which has the highest incidence rate for breast cancer in Europe. Today we know that breast cancer is no single disease. Conversely, multiple subtypes exist, with different molecular basis, clinical outcomes and response to treatment. The challenge we face is therefore to understand the characteristics of each breast ...